Media Contact
-
Boehringer Ingelheim GmbH
Dr Bernd Mann
Corporate Division Communications
55216 Ingelheim am Rhein
Germany
Press Conferences
Annual Press Conference 2009
-
21 April 2009
Boehringer Ingelheim Annual Press Conference 2009
Media event: Boehringer Ingelheim presents results of the business year 2008 and outlook 2009.
Venue:
Boehringer Ingelheim Headquarters
Ingelheim, Germany
21 April 2009, 10:30 hrs (CET)
Media: For Images and Videos please click on "Media Ressources" below. 
Congress Overview
News & Information
-
Annual Press Conference 2009
The year 2008 was again a successful year for Boehringer Ingelheim. The company achieved its selfset goals and maintained its growth path.
News Release Support Information
Boehringer Ingelheim showed stronger growth than the world pharmaceutical market for the ninth year in a row.
Speakers
Speakers
Prof. Dr Dr Barner presents the business development 2008 and outlook 2009 and gives an overview about Research and Development in 2008.
Prof. h.c. Dr Wolfram Carius gives an overview about the Biopharmaceuticals and the Industrial Customer business and about Human Resources.
Engelbert Tjeenk Willink gives an overview about the Prescription Medicines and Consumer Health Care business 2008.
Images
Images & Videos
-
Highlights of the Annual Press Conference 2009
Video taken during the Annual Press Conference
on 21 April 2009
-
Webcast on Demand Video
Webcast on Demand video taken during the Annual Press Conference
on 21 April 2009
-
"2008 was again a successful year for Boehringer Ingelheim. We achieved the goals we set ourselves and maintained our growth path, and this despite the changes in the global pharmaceutical market and the crisis in the international financial system", said Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine.
-
"Boehringer Ingelheim has now been an independent family-owned company for more than 124 years. The declared goal is to preserve this independence in the future too. Solid financing, sustainable entrepreneurial success and valid business potentials form the basis for a successful continuation", stated Hubertus von Baumbach, Head of Corporate Board Division Finance and Animal Health.
-
"Put in figures, we in 2008 again posted strong growth of currency-adjusted +9.5% and +5.9% on a euro-basis, with net sales of €11.6 billion. We thereby grew more strongly than the world pharmaceutical market for the ninth year in a row", stated Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine.
-
"The Consumer Health Care business will in future be given greater strategic significance for Boehringer Ingelheim, as the healthcare systems globally, with a view to cost control, will increasingly turn to over-the-counter medicines", mentioned Engelbert Tjeenk Willink, Head of Corporate Board Division Marketing and Sales Human Pharma.
-
In 2008, Boehringer Ingelheim created 1,500 new jobs. "The company's greatest asset, are our 41,300 employees. They are the core of our unique corporate culture as a family-owned company, which we wish to preserve and which we will develop further", said Prof. h.c. Dr Wolfram Carius, Head of Corporate Board Division Human Resources and Operations.
-
Prof. Dr Dr Andreas Barner
Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine.
-
Prof. h.c. Dr Wolfram Carius
Head of Corporate Board Division Human Resources and Operations.
-
Engelbert Tjeenk Willink
Head of Corporate Board Division Marketing and Sales Human Pharma.
